CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer

Stock Information for Cel-Sci Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cel-Sci Corporation

CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results
CEL-SCI's Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline
CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules
CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules
FDA's Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI's Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients
CEL-SCI Announces Closing of Public Offering
CEL-SCI Announces Pricing of Public Offering
CEL-SCI Announces Proposed Public Offering

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.